Didier has 30 years’ experience in drug delivery using colloids, ranging from basic research to clinical trials. He has collaborated with BioChem Pharma, GSK, Sanofi Pasteur and Chiron-Novartis on the evaluation of nasal vaccine using nanotechnologies. As an international expert in nanomedicine, he presided at the French Society for Controlled Release, was a board member of the French Society of Nanomedicine, and has over 110 international publications and 23 patents.
After a PhD on drug targeting in collaboration with the World Health Organization, Didier developed a patented technology for vaccine applications based on polysaccharidic nanoparticles with a phospholipid bi-layer.
His experience, innovative research and patented technology are at the heart of Vaxinano.
Beatrice has 30 year’s experience as CFO in international companies.
She was responsible for the administrative, financial, logistic and commercial development of these companies.
She joined Vaxinano as Chief financial officer.
Angelo joined VAXINANO in May 2019 as a project manager, with 7 years of experience as an engineer and then R&D manager in a start-up specialized in microbiology and fermentative metabolites. He successfully managed the different key R&D steps starting with the characterization of fermentative metabolites, the design and follow-up of pre-clinical studies, the standardization of production and the transfer to a pharmaceutical structure for marketing .
Within Vaxinano, he is now in charge of monitoring and coordinating vaccine development projects.
He holds a PhD in microbiology, immunology, virology and parasitology from the University of Lille and a Master's degree in Biotechnology with a specialization in genomics and proteomics from the University of Lille.